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AKAPs integrate genetic findings for autism spectrum
disorders
G Poelmans1,2, B Franke2,3, DL Pauls4, JC Glennon1 and JK Buitelaar1
Autism spectrum disorders (ASDs) are highly heritable, and six genome-wide association studies (GWASs) of ASDs have been
published to date. In this study, we have integrated the findings from these GWASs with other genetic data to identify enriched
genetic networks that are associated with ASDs. We conducted bioinformatics and systematic literature analyses of 200 top-
ranked ASD candidate genes from five published GWASs. The sixth GWAS was used for replication and validation of our
findings. Further corroborating evidence was obtained through rare genetic variant studies, that is, exome sequencing and copy
number variation (CNV) studies, and/or other genetic evidence, including candidate gene association, microRNA and gene
expression, gene function and genetic animal studies. We found three signaling networks regulating steroidogenesis, neurite
outgrowth and (glutamatergic) synaptic function to be enriched in the data. Most genes from the five GWASs were also
implicated—independent of gene size—in ASDs by at least one other line of genomic evidence. Importantly, A-kinase anchor
proteins (AKAPs) functionally integrate signaling cascades within and between these networks. The three identified protein
networks provide an important contribution to increasing our understanding of the molecular basis of ASDs. In addition,
our results point towards the AKAPs as promising targets for developing novel ASD treatments.
Translational Psychiatry (2013) 3, e270; doi:10.1038/tp.2013.48; published online 11 June 2013
Introduction
Autism spectrum disorders (ASDs) are a group of pervasive
neurodevelopmental disorders that are characterized by
qualitative impairments in reciprocal social interaction and
communication as well as restricted, repetitive and stereo-
typed patterns of behavior, interests and activities. The ASDs
include autism, Asperger’s syndrome and pervasive develop-
mental disorder, not otherwise specified (Diagnostic and
Statistical Manual of Mental Disorders-fourth edition-text
revision (DSM-IV-TR)). Individuals with autism show impair-
ments in all three core symptom domains and an onset of
symptoms before 3 years of age, whereas Asperger’s
syndrome is characterized by social and behavioral impair-
ments in the presence of a normal language development
before age 3 years. Pervasive developmental disorder, not
otherwise specified, is diagnosed in people who do not meet
autism criteria for all three symptom domains and/or show a
later age of onset (DSM-IV-TR). The prevalence of ASDs is
estimated to be 0.5–1%,1–3 with B4 times more males than
females being affected by these disorders.4,5 Family and twin
studies show that ASDs are highly heritable, andB90% of the
phenotypic variance that is observed in these disorders can
be explained by genetic factors.5–7 Despite this high
heritability, the identification and replication of genetic
susceptibility factors for ASDs has proven challenging, as
the genetic architecture of these disorders is highly hetero-
geneous (see recent reviews8–10). Rare genetic variants that
predispose individuals to ASDs are currently thought to
account for 10–20% of all ASD cases.8,10 These variants include
rare mutations in single genes that can lead to monogenic
disorders (such as fragile X syndrome and tuberous sclerosis)
associated with ASD symptoms, or genes identified through
exome sequencing studies and copy number variations (CNVs),
with the latter constituting deletions or duplications of a large
variety of genes and potentially contributing to oligogenic forms
of ASDs.8–10 Common genetic variants for ASDs—for example,
single-nucleotide polymorphism (SNPs)—have also been iden-
tified through candidate gene and genome-wide association
studies (GWASs), and each variant is assumed to contribute
only a small increase in disease risk.7–9 To date, six GWASs for
ASDs have been published.11–16 In addition to many protein-
coding genes that are implicated in ASD pathophysiology,
increasing evidence indicates that microRNAs may also be
involved in ASD aetiology.17–20 In recent years, three main
biological ‘themes’ have emerged from genetic ASD findings,
namely steroid synthesis,21,22 growth and neurite outgrowth of
developing neurons,9,15,21–23 and synaptic function.8,9,23–25 In
this article, we integrate the most important findings from ASD
GWASs into protein signaling networks that are linked to these
biological themes, and provide corroborating evidence for these
networks from exome sequencing/mutation, CNV, microRNA
and other genetic data. Importantly, we find that signaling
cascades within and between the three networks are functionally
connected by A-kinase anchor proteins (AKAPs), which seem to
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be promising targets for the development of novel psychophar-
macological treatment for ASDs.
Materials and methods
Identification of candidate genes and finding corrobor-
ating evidence. The main characteristics of the six published
GWASs of ASDs published to date are presented in Table 1.
We used SNP data from five of these studies to compile a list
of top-ranked genes associated with ASDs (the cutoff for
association was Po1 10 4).11–15 The sixth GWAS16 was
used for validation and replication processes (see below), as it
was conducted on a discovery sample that was independent
of the discovery samples that were used in the five other
GWASs. The used SNPs included those that were located
within exonic, intronic or untranslated regions of genes or
found within 100 kilobases (kb) of downstream or upstream,
potentially regulatory26–29 sequences flanking a gene. Of note,
for the selection of SNPs from two of the GWASs, we used the
complete and detailed association results for the combined
discovery samples, rather than the lists of SNPs as they were
published, which included replication samples.11,13 In addition,
although our chosen statistical cutoff for association was
essentially an arbitrary threshold, it was used in four of the six
published ASD GWASs to designate ‘suggestive’ evidence of
association,11–13,16 and application of this cutoff provided us
with a manageable number of genes for our subsequent
analyses. Applying the above described SNP selection criteria
yielded a total of 200 genes from the five GWASs11–15
(Supplementary Table 1).
Subsequently, we searched the literature for rare genetic
variants—mutations and/or CNVs—that have been found in
people with ASDs to find genes that were also identified
through the five GWASs (Supplementary Table 1). We
searched for mutations that were identified in one or more
recently published exome sequencing studies30–34 and/or
candidate gene mutation studies in people with ASDs. In
addition, we searched for overlapping CNVs that were identi-
fied in people with ASDs through a genome-wide array-based
hybridization approach and/or that were ‘recurrent’, in that
they were observed in case studies of at least two unrelated
people with ASDs. Furthermore, we searched for GWAS
candidate genes that are targeted by ASD-implicated micro-
RNAs. MicroRNAs are very small RNAs that negatively
regulate the expression of multiple genes.17–20 We compiled
a list of microRNAs that have been repeatedly implicated in
the aetiology of ASDs (Supplementary Table 2), after which
we used Targetscan to identify which of the 200 ASD
candidate genes are targeted and hence downregulated by
ASD-implicated microRNAs. Targetscan is a web-based tool
(http://www.targetscan.org/) that predicts possible gene
targets of microRNAs and ranks the predicted efficacy of
microRNA targeting using a calculated context score.
Finally, we searched the literature for ‘other’ genetic
evidence implicating the GWAS candidate genes in ASDs,
including data from candidate gene association studies, gene
expression studies, gene/protein function studies and genetic
animal studies. In addition, we compiled a list of 33 additional
ASD candidate genes that were not directly observed in the
top-ranked GWAS findings but are implicated in ASDs
through at least two independent lines of (strong) genetic
evidence (see Supplementary Table 3).
Bioinformatics analysis. To detect enriched gene cate-
gories in the 200 top-ranked candidate genes from the five
GWASs, we performed a bioinformatics analysis using the
Ingenuity Pathway Analysis software package (http://www.
ingenuity.com) (see Supplementary Table 4). Based on the
Ingenuity Knowledge Base—which draws on information
from the published literature as well as many other sources,
including gene expression and gene annotation databases—
genes are assigned to different categories and subcategories
of functionally related genes. The Ingenuity Pathway Analysis
program calculates single P-values for the enrichment of
each gene category and subcategory using the right-tailed
Fisher’s exact test. For each category and subcategory, a
multiple testing corrected P-value, calculated using the
Benjamini–Hochberg correction, is also provided.
Literature analysis and identification of protein net-
works. Subsequently, we systematically searched the lit-
erature for the (proposed) function of all proteins derived
from the ASD candidate genes using two databases: the
Uniprot Protein Knowledgebase (UniProtKB) (http://www.
uniprot.org/uniprot) and PubMed (http://www.ncbi.nlm.
nih.gov/sites/entrez).
For each ASD candidate from the five GWASs, we first
looked at the available information in UniProtKB, which in
most cases already provided a general indication of the
(putative) function of the gene or encoded protein in question.
Based on the Ingenuity analysis, UniProtKB and the three
main biological ‘themes’ linking the genetic ASD findings
(see Introduction), we subsequently searched PubMed using
the search terms ‘Leydig’, ‘steroid’, ‘steroid synthesis’,
‘steroidogenesis’, ‘testosterone’, ‘estradiol’, ‘estrogen’, ‘brain’,
‘neuron’, ‘neuronal growth’, ‘neurite’, ‘neurite outgrowth’,
‘synapse’, ‘synaptic’, ‘glutamate’ and ‘glutamate receptor’ in
combination with the name of each candidate gene (or
encoded protein). Guided by the literature we found, we also
searched PubMed for functional interactions between the
candidate genes/encoded proteins.
Replication and validation. Using the above described
SNP selection criteria, we compiled a list of top-ranked genes
from GWAS 6,16 and we subsequently searched for over-
lapping genes between this study and the five GWASs that
were considered in the aforementioned analyses.11–15 We
also systematically searched the literature using UniProtKb
and PubMed (see above) for the (proposed) function of the
proteins encoded by all top-ranked genes from the sixth
GWAS, and based on this information, we then tried to
(putatively) place each protein in one or more of the three
identified networks.
Results
Identification of candidate genes and finding corrobor-
ating evidence. As stated, six GWASs of ASDs have been
published to date (Table 1). Applying the SNP selection
criteria described in the Materials and methods section to
AKAPs integrate genetic findings for ASDs
G Poelmans et al
2
Translational Psychiatry
data from the five GWASs11–15 yielded a total of 200 ASD
candidate genes (Supplementary Table 1). Corroborating
evidence for a role of these genes in ASD aetiology (see
Materials and methods for criteria), was found through rare
variant studies. We found that 11 of the 200 candidate genes
from the GWASs (5.5%) were reported to contain mutations
in people with ASDs (Supplementary Table 1), including
findings from 5 recently published ASD exome sequencing
studies.30–34 In addition, 93 of the 200 GWAS candidate
genes (46.5%) have been observed in CNVs in people with
ASDs (Supplementary Table 1). Furthermore, we found that
100 (50%) of the GWAS-identified candidate genes were
targets of ASD-implicated microRNAs (see Materials and
methods, Supplementary Table 1 and Supplementary
Table 2). Lastly, 28 of the 200 GWAS candidate genes
(14%) are additionally implicated in ASD aetiology through
other genetic evidence, including data from candidate gene
association studies, gene expression studies, gene/protein
function studies and genetic animal studies (Supplementary
Table 1). Through literature study, we also added 33
strong ASD candidate genes, including CNTNAP2,35,36
MET 37,38 and NRXN1,39,40 implicated in the disorder
through at least two independent lines of strong genetic
evidence other than GWASs (Supplementary Table 3).
Bioinformatics analysis. For the 200 top-ranked ASD
GWAS genes, the Ingenuity pathway software revealed a
significant enrichment (multiple testing corrected P¼ 1.64
 10 4) of the gene category ‘neurological disease’, with 81
of the 200 genes falling into this category. Moreover, 8 of the
9 other significant categories in the top 10 of nervous system-
related gene categories could be directly linked to neurite
outgrowth or synaptic function (Supplementary Table 4).
Literature analysis and identification of protein net-
works. On the basis of the findings from the Ingenuity
analysis and our systematic literature analysis (see Materials
and methods), we found that the proteins encoded by 150 of
the 233 above mentioned ASD candidate genes (64%) fit into
three distinct signaling networks that correspond very well to
the three aforementioned biological themes for ASDs. The
first network is involved in regulating the production and
metabolism of the steroid hormones testosterone and
estradiol in testicular Leydig cells (Figure 1), whereas the
second network relates to directed neurite outgrowth, and
integrates molecular signaling cascades in the extracellular
matrix, cell membrane, cytoplasm and nucleus of developing
neurons (Figure 2a) with signaling cascades that modulate
the cytoskeleton in and the extracellular matrix that
surrounds the growth cone of these neurons (Figure 2b).
The third network regulates and modulates (glutamatergic)
neurotransmission across the synapse (Figure 3). A detailed
description of the evidence linking all the genes and encoded
proteins in the networks shown in Figures 1–3 is provided in
the Supplementary Information. Importantly, signaling cas-
cades within all three networks are modulated and regulated
by the proteins encoded by 10 ASD-implicated AKAP genes
(Supplementary Table 5).
Replication and validation. As indicated in the Materials
and methods section, the sixth ASD GWAS by Anney et al.16
was used for validation and replication purposes, as it was
entirely independent of the five other published ASD
GWASs.11–15 A total of 15 genes from GWASs 1–5 (7.5%)
were directly replicated—they were implicated through SNPs
that meet the selection criteria of this study in 2 of the 6
published GWASs—and 13 of these genes were found in
GWAS 6 (Supplementary Table 6). In addition, the proteins
encoded by 111 of the 333 top-ranked (protein coding) genes
from GWAS 6 (33%) could be placed in one or more of the
three identified networks (Supplementary Table 7), which
provides a strong validation of the involvement of these
Table 1 Overview of the clinical samples from six published GWASs of ASDs11–16
GWAS Clinical sample Genotyping
platform
Phenotype Diagnosis
Wang et al.11 Combined discovery sample (AE): AGRE (943 families) a þ ACC
cohort (1453 cases and 7070 controls) from CHOP and several
other US clinical sites
Illumina ASD ADOSþADI-R
Ma et al.12 CAP discovery sample (AE): four US clinical sites (438 families) Illumina Autism ADI-RþDSM-IV
Weiss et al.13 Combined discovery sample (AE), consisting of 1031 multiplex
families with 1553 affected offspring from: AGRE (801 families) a
þ NIMH (341 families)
Affymetrix ASD ADI-R
Salyakina et al.14 Combined sample: discovery sample from two US clinical sites
(124 families) þ AGRE validation sample (110 families)
Illumina ASP ADI-RþDSM-IV
Hussman et al.15 Combined sample: sample from two US clinical sites (597 families)
þ AGRE sample (696 families)
Illumina Autism ADI-RþDSM-IV
Anney et al.16 AGP Consortium discovery sample (AE): Autism (809 families) þ
ASD (1369 families)
Illumina AutismþASD ADOSþADI-R
Abbreviations: ACC, Autism Case Control; ADOS, Autism Diagnostic Observation Schedule; ADI-R, Autism Diagnostic Interview-Revised; AE, all ethnicities; AGP,
Autism Genome Project; AGRE, Autism Genetic Resource Exchange; ASD, autism spectrum disorder; ASP, Asperger’s syndrome; CAP, Collaborative Autism
Project; CHOP, Children’s Hospital of Philadelphia; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders-fourth edition; GWAS, genome-wide association
study; NIMH, National Institute for Mental Health.
aThere is considerable overlap between these two clinical samples.11,13
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networks in ASD aetiology. In this respect, it is also very
intriguing that an intronic SNP in NQO2, a gene that had
already been implicated in ASD aetiology (Supplementary
Table 3) and that encodes a protein with an important
function in the identified steroidogenesis and neurite out-
growth networks (see Figures 1 and 2a, and Supplementary
Information), yields genome-wide significant association
(P¼ 2 10 15) with ASD in GWAS 6 (Supplementary
Table 7).
Potential statistical bias. An important potential bias in the
analysis of the top findings from GWASs is the fact that large
genes, which are often brain expressed, may be more likely
found as associated with a phenotype in a GWAS as a result
of chance, as more SNPs are present in these large genes.41
Indeed, the genes found among the top findings of ASD
GWASs 1–5 were considerably larger than the average gene
size of the human genome, with the 200 (unique) ASD
candidate genes having an average size of 221 kb
(Supplementary Table 8) versus an average gene size in
the human genome of 27 kb.42
In order to test whether the GWAS genes included in this
study were likely to constitute false positive findings, we
looked for confirmation from other types of genetic studies and
we performed a comparative analysis of the top ranked
GWAS findings from unrelated disorders. First, a total of 111
of the 200 candidate genes from GWASs 1–5 were also
implicated in ASDs through rare genetic variants—that is,
mutations and/or CNVs affecting the gene in people with
ASDs—and/or other genetic evidence, which includes SNPs/
common genetic variants from classic candidate gene
association studies, gene expression and function studies
and genetic animal studies (Supplementary Table 1).
Most importantly, 42 of the 47 (unique) large genes (size
4250 kb) from GWASs 1–5 (89%) and all of the 26 very large
genes (size 4500 kb) were implicated in ASD aetiology
through at least one additional line of genetic evidence
(Supplementary Tables 1 and 8). Second, arguing that if large
Figure 1 Schematic representation of a protein network that is implicated in autism spectrum disorders (ASDs) through regulating the production and metabolism of the
steroid hormones testosterone and estradiol in testicular Leydig cells. The proteins encoded by genes implicated in ASDs through common genetic variants—single-nucleotide
polymorphisms (SNPs) from five published genome-wide association studies (GWASs) (Supplementary Table 1) and/or ASD candidate gene association studies—are
indicated in yellow. The proteins encoded by genes implicated in ASD aetiology through rare genetic variants—one or more mutations and/or copy number variations (CNVs)
affecting the gene—are indicated in red, whereas the proteins encoded by genes implicated in ASDs through both common and rare genetic variants are indicated in orange.
In addition, all A-kinase anchor proteins (AKAPs) are dark blue and the proteins encoded by genes that have been implicated in ASD aetiology through ‘other’ genetic
evidence—including gene expression studies, gene/protein function studies and genetic animal studies—have a green border. In the Supplementary Information, the network
is described in detail, and the current knowledge about the function of the network proteins is presented.
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genes are more likely found to be associated with a phenotype
of a GWAS because of chance, this would be expected to be
the case for GWASs of nonpsychiatric disorders as well.
Therefore, we compared the results of our Ingenuity
analyses of the 20 top ASD candidate genes from GWASs
1–5 with those for the top 20 candidate genes from four
published GWASs for diabetes mellitus type I and Crohn’s
disease (Supplementary Tables 9 and 10), two polygenic
disorders that are assumed not to primarily originate in
the brain. This comparison showed that the neurological
disease category was significantly enriched in the ASD
GWAS findings (with 9 of the 20 top genes falling into this
category), only contained a single gene in diabetes type I and
was not enriched at all in Crohn’s disease (Supplementary
Table 10).
Discussion
In this study, we used both bioinformatics and extensive
manual literature mining to integrate the top-ranked findings of
six published GWASs of ASDs into three biological pro-
cesses. In addition, we have comprehensively addressed the
subject of possible gene size-based bias.
Importantly, we found that many of the genes encoding
proteins in the three networks have been implicated in ASD
aetiology through both common genetic variants (that is,
SNPs from GWASs and classic candidate gene association
studies) and rare genetic variants (that is, one or more
mutations and/or CNVs affecting the gene in people
with ASDs). All these proteins are indicated in orange in
Figures 1–3, and this finding suggests that the often made
distinction between rare and common genetic ASD variants
(see above) is somewhat artificial: to a considerable extent,
multifactorial and oligogenic forms of ASDs—caused by
common and rare genetic variants, respectively—seem to
share aetiologic pathways.
On the matter of potential gene size-based bias, and based
on the corroborating evidence from other sources as well as
the analysis of unrelated nonpsychiatric disorders, we would
like to submit that the (vast) majority of the ASD candidate
genes from the GWASs were not identified because of gene
size bias and therefore represent true associations. The
corroborating evidence for many of the large(r) GWAS genes
comes from mutation, CNV, microRNA and other genetic data
that are not subjected to potential gene size bias, as well as
from the replication and validation through an entirely
independent additional GWAS (GWAS 6). We have come to
our conclusion about the absence of gene size-based bias
despite the fact that our chosen statistical cutoff for associa-
tion (Po1 10 4) is essentially an arbitrary threshold. It is
below the commonly used threshold for genome-wide
significant association (Po5 10 8),11–16 but was chosen
because it is often used to designate ‘suggestive’ association
(for example, in four published ASD GWASs11–13,16) and
because it provided us with a manageable number of genes
for subsequent analyses.
Using a threshold below the genome-wide significance level
(in conjunction with validation through other genetic data) is
also supported by polygenic analyses showing that many
signals from GWASs, although not reaching genome-wide
significance individually, contribute to a given trait or
disease.43,44 That being said, we explicitly do not wish to
exclude the possibility that a number of GWAS-identified ASD
candidate genes are spurious findings.
The three ASD networks we describe fit very well with the
three biological themes that have already emerged from
diverse types of ASD studies (see above), which adds further
weight to our findings. The identified networks have important
implications for advancing our understanding of the molecular
basis of ASDs. First, the testicular steroidogenesis network
provides additional proof for both the excess of males in ASDs
(see above) and the ‘extreme male brain’ theory of ASDs. This
theory integrates several lines of evidence and states that
ASD behaviors are associated with increased fetal testoster-
one levels and are therefore more common in males, as well
as in females with disorders characterized by an over-
production of testosterone.45,46 Furthermore, our findings
relating to the involvement of disturbed neurite outgrowth and
synaptic function in the genetic aetiology of ASDs fit very well
with literature reports describing aberrant structural and
functional brain connectivity in people with ASDs.47 Hence,
ASDs can be seen as disorders of ‘neuronal communication’
that, at the level of individual neurons, could be caused by
disturbances or alterations in the efficiency, direction and/or
timing of neurite outgrowth (during brain development) and/or
synaptic function (throughout adult life). This is further
corroborated by a study reporting enrichment of several
neurite outgrowth-related and ASD-implicated genes in a set
of genes that were correlated with structural connectivity in the
adult rat brain through gene expression patterns during brain
development.48
Despite being important contributing factors, impairments
of neurite outgrowth and synaptic function are not specific to
the aetiology of ASDs, and our research group has previously
reported that (impaired) neurite outgrowth is also important in
the genetic aetiology of dyslexia49 and attention deficit
hyperactivity disorder,50 two neurodevelopmental disorders
that show high comorbidity and are genetically correlated with
each other51 and with ASDs.52–54 Impaired synaptic function
is also implicated in the aetiology of schizophrenia,55 a
neurodevelopmental disorder that manifests in late adoles-
cence or early adulthood and shares genetic factors with
ASDs.56 Nevertheless, we believe that the clinical specificity
of these neurodevelopmental disorders could be at least
partially explained by the different functional consequences of
disturbed or abnormal neurite outgrowth and/or synaptic
function in the most affected brain region(s) for each disorder.
The cerebellum and, more specifically, cerebellar Purkinje
cells have been consistently found to be among the most
affected brain regions in ASDs, with the disorders often linked
to an actual loss of these cells.57,58
As several of the ASD-implicated microRNAs show
dysregulated expression in post-mortem cerebellar cortex of
people with ASDs,17 and many of the proteins encoded by
identified ASD candidate genes—including the ASD-impli-
cated AKAP5, AKAP9 and AKAP11 (see below)—are highly
expressed and/or have a specific function in cerebellar
Purkinje cells (see Supplementary Tables 1,3,4 and 6),
cerebellar dysfunction of the identified genetic networks may
be very important in the aetiology of ASDs.
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As already indicated above, the proteins encoded by 10
AKAP genes (AKAP5, AKAP7, AKAP8, AKAP9, AKAP10,
AKAP11, AKAP13, MAP2, MSN and NBEA) constitute a
common functional theme within the identified networks. The
AKAPs constitute a growing protein family of currently more
than 50 members that share an ability to bind protein kinase A
(PKA) to its substrates, that is, the proteins that are
phosphorylated and hence regulated in their activity by PKA.
AKAPs are found in many subcellular locations and expressed
in many tissues, including testis and brain. Apart from
anchoring PKA, AKAPs can also directly bind and/or regulate
many other proteins, including kinases other than PKA and
phosphatases.59 As shown and described in Figures 1–3 and
the Supplementary Information, ASD-implicated AKAPs are
involved in signaling cascades regulating Leydig cell-based
steroidogenesis, neurite outgrowth of developing neurons and
glutamatergic synaptic transmission. Within the neurite out-
growth network, AKAPs also regulate the two main signaling
‘hubs’, by regulating both the activity of CDC42 and (the
transcription factor function of) CTNNB. Furthermore, in a
study using weighted gene coexpression analysis in human
neuronal progenitor cells, it was reported that AKAP7 and
AKAP11 are coexpressed in a ‘coexpression module’ contain-
ing genes—including previously implicated ASD candidate
genes—that are likely to be involved in the onset of
differentiation as well as the cessation of proliferation of these
cells.60 Lin et al.61 reported that MAP2 and NBEA, two AKAP
genes that have been strongly implicated in ASD aetiology
(Supplementary Table 4), as well as a large number of
(candidate) genes from the identified networks, including the
two AKAP-regulated network ‘hubs’ CDC42 and CTNNB,
undergo significant changes in their expression during the
transition from pluripotent stem cells to early differentiating
neurons. All these data provide further evidence for the
functional involvement of the identified protein networks as
well as specific ASD-implicated AKAPs in early brain
development.
In addition, there is ample genetic evidence for the
involvement of the 10 AKAPs in the aetiology of ASDs
(Supplementary Table 5). First, six AKAP genes (AKAP7,
AKAP10, AKAP11, MAP2, MSN and NBEA) are implicated to
have a role in these disorders through SNP associations that
have been detected in the published GWASs11,16 and/or a
recent candidate gene association study.62 In this respect,
rs5918959, a SNP located 66 kb downstream of the moesin
(MSN) gene, showed a genome-wide significant P-value of
1.22 10 10 for association with ASDs in the combined
discovery samples from the GWAS by Wang et al.11
Furthermore, eight AKAP genes (AKAP5, AKAP8, AKAP9,
AKAP10, AKAP13, MAP2, MSN and NBEA) have been found
in CNVs in people with ASDs63–73 and NBEA was found to be
disrupted by a chromosomal translocation in a male with
autism.73 AKAP9 is also present in a locus linked to autism.74
Moreover, five AKAP genes are targets of ASD-implicated
microRNAs (AKAP5, AKAP8, AKAP11, AKAP13 and NBEA)
(Supplementary Tables 2 and 5) or expressed differentially in
lymphoblastoid cells of people with ASDs (AKAP7).20
Expression studies also implicate MSN and MAP2 with
increased75 and decreased76 expression, respectively, found
in the post-mortem brain of autistic people. In addition,
exposure to low levels of polychlorinated biphenyls in rats
leads to increased cerebellar expression of Akap11 (ref. 77)
and autism-like behavior.78 Recently, it was also reported
thatNbeaþ / mice—that is, mice that are haploinsufficient for
the Nbea gene—exhibit several ASD-like features, including
changes in social behaviors as well as spatial learning and
memory.79
An eleventh AKAP gene is implicated in ASDs, in that
rs10038113, a SNP yielding genetic association with ASDs in
the GWASs by Wang et al.11(P¼ 7.40 10 8) and Ma
et al.12(P¼ 3.40 10 6), maps only 7 kb upstream of the
moesin pseudogene 1 (MSNP1) gene (http://www.ensembl.
org). Although Wang et al.11 speculate that CDH10 and/or
CDH9—two cadherin genes that are located 1257 kb
upstream and 978 kb downstream of rs10038113,
respectively—may be implicated in this association, MSNP1
is the only gene in a linkage disequilibrium block ofB100 kb in
size that contains rs10038113 as well as several SNPs
yielding genome-wide significant associations with ASDs for
the combined discovery and replication samples in the GWAS
they published.11 Interestingly, rs10038113 and rs1896731, a
SNP present in the same linkage disequilibrium block and
mapping 11 kb upstream of MSNP1, were recently also found
to be nominally associated with autistic traits,80 whereas
rs4307059, a SNP from the linkage disequilibrium block that is
located 56 kb downstream of MSNP1, associates with ASD-
like social communication difficulties in the general popula-
tion.81 Moreover and most importantly, MSNP1 shows a very
Figure 2 (a) Schematic representation of a protein network that is implicated in autism spectrum disorders (ASDs) and leads to neurite outgrowth through molecular
signaling cascades located in the extracellular matrix/compartment, cell membrane, cytoplasm and nucleus of developing neurons. The proteins encoded by genes implicated
in ASDs through common genetic variants—single-nucleotide polymorphisms (SNPs) from five published genome-wide association studies (GWASs) (Supplementary
Table 1) and/or ASD candidate gene association studies—are indicated in yellow. The proteins encoded by genes implicated in ASD aetiology through rare genetic variants—
one or more mutations and/or copy number variations (CNVs) affecting the gene—are indicated in red, whereas the proteins encoded by genes implicated in ASDs through
both common and rare genetic variants are indicated in orange. In addition, all A-kinase anchor proteins (AKAPs) are dark blue and the proteins encoded by genes that have
been implicated in ASD aetiology through ‘other’ genetic evidence—including gene expression studies, gene/protein function studies and genetic animal studies—have a
green border. In the Supplementary Information, the network is described in detail, and the current knowledge about the function of the network proteins is presented.
(b) Schematic representation of a protein network that is implicated in ASDs and leads to neurite outgrowth through molecular signaling cascades located in the growth cone
and surrounding extracellular matrix/compartment of developing neurons. The proteins encoded by genes implicated in ASDs through common genetic variants—SNPs from
five published GWASs (Supplementary Table 1) and/or ASD candidate gene association studies—are indicated in yellow. The proteins encoded by genes implicated in ASD
aetiology through rare genetic variants—one or more mutations and/or copy number variations (CNVs) affecting the gene—are indicated in red, whereas the proteins
encoded by genes implicated in ASDs through both common and rare genetic variants are indicated in orange. In addition, all AKAPs are dark blue and the proteins encoded
by genes that have been implicated in ASD aetiology through ‘other’ genetic evidence—including gene expression studies, gene/protein function studies and genetic animal
studies—have a green border. In the Supplementary Information, the network is described in detail, and the current knowledge about the function of the network proteins is
presented.
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high degree of sequence homology to the MSN gene82 and
was recently demonstrated to regulate the expression ofMSN
in the human cerebral cortex through expression of its
antisense strand.83
Additional functional evidence points to a role for the AKAP
genes (and the encoded proteins) in the aetiology of ASDs.
AKAP10,84 AKAP13,85 and MSN86 are involved in innate
immunity, known to be disturbed in at least a subset of people
with ASDs,87,88 through regulation of the activity of Toll-like
receptors. AKAP5 and AKAP8 are both involved in the
biosynthesis of the circadian hormone melatonin,89 which is
markedly disturbed in people with ASDs.90 Thus, it is
interesting that both anti-inflammatory treatments and melato-
nin have been proposed as possible new treatments of
ASDs.91 Neuronal AKAPs also play an important role in the
serotonin-induced release of neurotransmitters.92 AKAP5 is
involved in the recycling of postsynaptic a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid-type glutamate receptors
(Figure 3) and the regulation of long-term potentiation and
depression through glutamate-bound N-Methyl-D-aspartate
(NMDA)-type receptors.93,94 AKAP7 regulates signaling cas-
cades downstream of D1-like dopamine receptors.95,96 Hence,
it is interesting and intriguing that risperidone, one of only two
drugs approved by the Food and Drug Administration (FDA) for
the treatment of ASDs (http://www.fda.gov/), functions both as
a modulator of a-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionic acid- and NMDA-type glutamate receptor expression97
and regulates the serotonin-induced release of glutamate and
dopamine.98,99
Risperidone is also involved in upregulating the brain
expression of microtubule-associated protein 2 (MAP2)100—an
AKAP that is implicated in neurite outgrowth (Figure 2b)—as
well as CTNNB and GSK3B,101 the two proteins that are
regulated by AKAP8 and AKAP11, respectively (Figure 2a).
RHOA, a protein that is positively regulated by AKAP13 and
has an important role in the neurite outgrowth and synaptic
networks (Figures 2a, b and 3), also modulates the effects of
risperidone treatment for autistic symptoms.102
In summary, 8 of the 10 ASD-implicated AKAPs that
we identified in our analyses—AKAP5, AKAP7, AKAP8,
Figure 3 Schematic representation of a protein network that is located in the neuronal synapse and implicated in autism spectrum disorders (ASDs) by its involvement in
modulating glutamatergic neurotransmission. The proteins encoded by genes implicated in ASDs through common genetic variants—single-nucleotide polymorphisms (SNPs)
from five published genome-wide association studies (GWASs) (Supplementary Table 1) and/or ASD candidate gene association studies—are indicated in yellow. The
proteins encoded by genes implicated in ASD aetiology through rare genetic variants—one or more mutations and/or copy number variations (CNVs) affecting the gene—are
indicated in red, whereas the proteins encoded by genes implicated in ASDs through both common and rare genetic variants are indicated in orange. In addition, all A-kinase
anchor proteins (AKAPs) are dark blue and the proteins encoded by genes that have been implicated in ASD aetiology through ‘other’ genetic evidence—including gene
expression studies, gene/protein function studies and genetic animal studies—are green/have a green border. In the Supplementary Information, the network is described in
detail, and the current knowledge about the function of the network proteins is presented.
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AKAP10, AKAP11, AKAP13, MAP2 and MSN—regulate two
ASD-implicated biological processes (innate immunity and
melatonin synthesis) for which new treatments have been
proposed and/or are involved in directly or indirectly modulat-
ing the downstream effects of risperidone treatment for ASDs.
The effects of existing ASD drugs on these and other AKAPs
should be investigated in future studies. In this respect,
several AKAP-dependent protein–protein interactions and the
AKAPs themselves are also increasingly considered and
investigated as potential drug targets,59 and several mole-
cules that specifically inhibit the binding of PKA to its AKAP-
binding site have been patented (http://www.wipo.int/
patentscope/search/en/detail.jsf?docId=EP14889042&recNum
=2&office=&queryString=EN_ALLTXT%3A%28AKAP%29&
prevFilter=&sortOption=Relevance&maxRec=255). One of
these molecules is Ht31, a peptide that is derived from
AKAP13. Interestingly, administration of Ht31 to rats effec-
tively blocks the ‘masculinization’ of a part of their brain,103
which suggests an additional and more direct role of AKAPs in
mediating the masculinizing effects of testosterone—or
rather, estradiol, which is converted from testosterone in
the brain104,105(see Figure 2a)—on brain development.
Furthermore, transgenic mice that conditionally express Ht31
in their hippocampus show spatial learning and memory
impairments106 that resemble cognitive deficits in ASDs.107,108
For these reasons, we think that the ASD-implicated AKAPs
and/or protein–protein interactions dependent on these
AKAPs are excellent targets for developing novel ASD drugs.
Conclusions
In this study, we used bioinformatics and literature analyses to
investigate and integrate the top-ranked findings of five
published GWASs of ASDs. We were able to place the
proteins encoded by 117 of the 200 ASD candidate genes
from these GWASs and 33 additional strong ASD candidates
into three signaling networks regulating steroidogenesis in
Leydig cells, neurite outgrowth and glutamatergic synaptic
function. Importantly, the sixth published GWAS of ASDs
strongly replicated and validated the identified networks.
Several members of the AKAP family functionally integrate
signaling cascades within and between the three identified
networks. Thus, these AKAPs—that are themselves strongly
genetically and functionally linked to ASDs—seem ideally
suited to be studied further as possible ‘druggable’ targets for
the treatment of ASDs.
There is also a strong overlap between rare and common
ASD-implicated genetic variants, which implies that multi-
factorial and oligogenic forms of ASDs partially share
aetiologic pathways. Furthermore, we have provided compel-
ling evidence against gene size-based bias within the ASD
GWAS data.
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